<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307175</url>
  </required_header>
  <id_info>
    <org_study_id>CIMS-2014-01</org_study_id>
    <nct_id>NCT02307175</nct_id>
  </id_info>
  <brief_title>A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication</brief_title>
  <official_title>A Phase I Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron (CYCLOTEC) in Patients With Thyroid Scan Indication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label single site study to demonstrate the safety and efficacy of Tc-99m
      pertechnetate produced by high energy cyclotron at CHUS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed clinical trial will be a prospective, case-controlled Phase I, open label,
      single site study. The first 10 consecutively enrolled patients will receive CYCLOTEC
      standard procedure thyroid imagery and an additional whole-body scans, and 20 subsequent
      case-matched controls, will receive GPERT and will also have additionnal whole body scan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of Tc99m produced by high-energy cyclotron (CycloTec)</measure>
    <time_frame>6 months</time_frame>
    <description>Equivalence of biodistribution of Tc99m produced by high-energy cyclotron (CycloTec) will be compared to the biodistribution of the conventional Tc99m pertechnetated (Case match: 1 CycloTec patient vs. 2 conventional Tc99m-pertechnetate patients)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Autoimmune Thyroid Disease</condition>
  <condition>Congenital Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Cyclotec</arm_group_label>
    <description>The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generator produced Tc99m-pertechnetate</arm_group_label>
    <description>20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients between 18 and 80 years of age with thyroid scan indication
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prescribed thyroid scan

          -  Provided written informed consent prior to participation

          -  Biochemical parameters within 5 times of the normal limits for age

          -  WBC count &gt; 3.0/μL

          -  ANC count 1.5/μL

          -  Platelets &gt; 75,000/μL

          -  Haemoglobin &gt; 10 g/dL

          -  Karnofsky Performance Scale score &gt; 50

        Exclusion Criteria:

          -  Nursing or pregnant females

          -  Biochemical parameters as measured outside 5 times the normal limits for age within 14
             days of the scan

          -  WBC &lt; 3.0/μL

          -  ANC &lt; 1.5/μL

          -  Platelets &lt; 75,000/μL

          -  Haemoglobin &lt; 10 g/dL

          -  Unable and unwilling to follow instructions and comply with the protocol

          -  Unable or unwilling to provide written informed consent prior to participation in the
             study

          -  Karnofsky Performance Scale score &lt; 50
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Turcotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Dr Éric E Turcotte, MD</investigator_full_name>
    <investigator_title>MD, Nuclear medicine specialist, Head of Clinical Research at CIMS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Congenital Hypothyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Pertechnetate Tc 99m</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

